[{"orgOrder":0,"company":"Adimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Adimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimmune \/ Not Applicable"},{"orgOrder":0,"company":"Adimmune","sponsor":"Eden Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Adimmune \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Adimmune \/ Adimmune"},{"orgOrder":0,"company":"Adimmune","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adimmune \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adimmune \/ Clover Biopharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Adimmune

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the preven...

                          Brand Name : AdimFlu-S

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 19, 2023

                          Lead Product(s) : Quadrivalent Influenza Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Clover Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Under the terms of the Master Service Agreement, JHL Biotech will support Adimmune Corporation to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 11, 2020

                          Lead Product(s) : Covid-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Eden Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Adimmune had designed and produced 4 prototypes of antigens to fight Covid-19 based on its recombinant protein technology, and has tested one prototype in a BSL-3 lab at National Taiwan University.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 06, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank